TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07760077: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Doses of QLS1510 Tablets in Healthy Adult Participants

Sponsor: Shanghai Qilu Pharmaceutical Research and Development Center LTD · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07760077 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07760077 Rescue Dossier →